Madagascar vs Syria: Access to anti-retroviral drugs, female (%)
Madagascar
39.0%
in 2024
Syria
41.0%
in 2024
Madagascar rank
128th
Syria rank
127th
Access to anti-retroviral drugs, female (%) over time
- Madagascar
- Syria
How they compare
Syria currently reports 41.0% against 39.0% in Madagascar, a difference of 2.0%.
That makes Syria's figure about 1.1 times Madagascar's.
Across all 25 years both countries report, Syria has been ahead every year.
Madagascar ranks 128th and Syria ranks 127th of 141 countries.
Syria has averaged higher in every one of the 3 decades both report.
Head to head by decade
| Decade | Madagascar | Syria | Difference | Ahead |
|---|---|---|---|---|
| 2000s | 0.4% | 5.4% | 5.0% | Syria |
| 2010s | 4.5% | 26.9% | 22.4% | Syria |
| 2020s | 24.6% | 41.4% | 16.8% | Syria |
Averages of every year both report within each decade.
Frequently asked questions
- Which has higher access to anti-retroviral drugs, female, Madagascar or Syria?
- Syria, at 41.0% against 39.0% in Madagascar as of 2024.
- What is the difference in access to anti-retroviral drugs, female between Madagascar and Syria?
- 2.0%, with Syria ahead.
- How many years of comparable data are there for Madagascar and Syria?
- 25 years are reported by both, from 2000 to 2024.
- How do Madagascar and Syria rank globally for access to anti-retroviral drugs, female?
- Madagascar ranks 128th and Syria ranks 127th of 141 countries.
- Where does this data come from?
- UNAIDS estimates, published as Access to anti-retroviral drugs, female (%). Statizoid refreshes it automatically from the source and publishes the full history for both places.
Individual pages
About this data
The percentage of adult females living with HIV who are receiving antiretroviral therapy.